Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
NTRA

Natera Inc

NTRA

58.15USD+0.21 (+0.36%)Market Closed
Watchlist

Market Summary

USD58.15+0.21
Market Closed
0.36%

NTRA Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

NTRA Stock Price

View Fullscreen

NTRA RSI Chart

NTRA Valuation

Market Cap

6.9B

Price/Earnings (Trailing)

-13.86

Price/Sales (Trailing)

7

EV/EBITDA

-13.43

Price/Free Cashflow

-22.22

NTRA Price/Sales (Trailing)

NTRA Profitability

EBT Margin

-50.45%

Return on Equity

-63.64%

Return on Assets

-34.52%

Free Cashflow Yield

-4.5%

NTRA Fundamentals

NTRA Revenue

Revenue (TTM)

988.7M

Revenue Y/Y

27.38%

Revenue Q/Q

2.64%

NTRA Earnings

Earnings (TTM)

-499.3M

Earnings Y/Y

10.25%

Earnings Q/Q

1.6%

Price Action

Last 7 days

-0.5%

Last 30 days

40.7%

Last 90 days

7.3%

Trailing 12 Months

50.0%

How does NTRA drawdown profile look like?

NTRA Financial Health

Current Ratio

4.37

NTRA Investor Care

Shares Dilution (1Y)

22.29%

Diluted EPS (TTM)

-4.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023867.8M931.0M988.7M0
2022667.3M723.5M776.0M820.2M
2021449.3M504.9M564.8M625.5M
2020329.5M341.6M361.9M391.0M
2019262.1M273.4M286.1M302.3M
2018222.6M233.4M242.7M257.7M
2017204.6M204.9M206.9M209.6M
2016204.8M211.7M220.7M217.1M
2015179.4M188.7M187.3M190.4M
201481.2M107.2M133.3M159.3M
201300055.2M

Latest Insider Trading transactions for NTRA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 29, 2023
chapman rowan e
sold
-111,831
55.9714
-1,998
-
Nov 21, 2023
marcus gail boxer
sold
-54,313
54.3136
-1,000
-
Nov 20, 2023
chapman steven leonard
sold
-141,130
55.00
-2,566
ceo and president
Nov 02, 2023
sheena jonathan
sold
-201,150
40.23
-5,000
-
Nov 02, 2023
sheena jonathan
sold
-20,236
40.472
-500
-
Nov 02, 2023
sheena jonathan
sold
-20,115
40.23
-500
-
Oct 27, 2023
healy james
acquired
16,869
42.6
396
-
Oct 27, 2023
rosenman herm
acquired
19,340
42.6
454
-
Oct 27, 2023
baynes roy d.
acquired
13,717
42.6
322
-
Oct 23, 2023
sheena jonathan
sold
-20,018
40.037
-500
-

1–10 of 50

Which funds bought or sold NTRA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
55.86
2,377,000
8,072,710
0.01%
Nov 27, 2023
TRUST CO OF VERMONT
unchanged
-
-463
4,646
-%
Nov 27, 2023
BANQUE PICTET & CIE SA
added
7.33
-155,290
6,321,110
0.07%
Nov 27, 2023
AllSquare Wealth Management LLC
unchanged
-
-283
4,425
-%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-92.63
-3,775,930
271,076
-%
Nov 22, 2023
Polar Capital Holdings Plc
reduced
-38.34
-316,342
403,826
-%
Nov 22, 2023
Public Sector Pension Investment Board
sold off
-100
-4,622,700
-
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-521,537
-
-%
Nov 21, 2023
Walleye Capital LLC
new
-
5,514,740
5,514,740
0.01%
Nov 21, 2023
COMERICA BANK
new
-
7,936
7,936
-%

1–10 of 37

Latest Funds Activity

Are funds buying NTRA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NTRA
No. of Funds

Schedule 13G FIlings of Natera Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 06, 2023
blackrock inc.
4.9%
5,509,188
SC 13G/A
Feb 14, 2023
alger associates inc
8.2%
8,972,721
SC 13G/A
Feb 09, 2023
vanguard group inc
9.01%
9,945,514
SC 13G/A
Feb 03, 2023
blackrock inc.
5.1%
5,566,743
SC 13G
Jan 23, 2023
jpmorgan chase & co
5.6%
6,211,632
SC 13G/A
Jun 09, 2022
blackrock inc.
4.9%
4,706,415
SC 13G
Feb 14, 2022
alger associates inc
7.2%
6,805,028
SC 13G/A
Feb 03, 2022
blackrock inc.
7.4%
7,010,757
SC 13G/A
Jan 24, 2022
jpmorgan chase & co
5.3%
5,025,967
SC 13G
Feb 16, 2021
alger associates inc
7.28%
6,217,680
SC 13G

Recent SEC filings of Natera Inc

View All Filings
Date Filed Form Type Document
Dec 08, 2023
144
Notice of Insider Sale Intent
Dec 08, 2023
4
Insider Trading
Dec 01, 2023
4
Insider Trading
Nov 29, 2023
144
Notice of Insider Sale Intent
Nov 22, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 21, 2023
144
Notice of Insider Sale Intent
Nov 20, 2023
144
Notice of Insider Sale Intent
Nov 09, 2023
10-Q
Quarterly Report
Nov 08, 2023
8-K
Current Report

Peers (Alternatives to Natera Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
160.7B
29.6B
10.51% -19.98%
27.16
5.44
-5.39% -12.54%
44.1B
3.6B
24.23% 23.99%
53.65
12.3
7.43% 22.86%
37.3B
7.0B
16.28% -18.61%
32.89
5.33
5.03% -14.68%
15.2B
9.3B
1.84% -9.68%
19.95
1.64
-9.69% -38.22%
11.7B
2.4B
2.99% 40.82%
-41.48
4.86
19.99% 60.62%
MID-CAP
10.5B
4.2B
16.20% -2.67%
22.08
2.49
11.49% 8.84%
8.7B
1.8B
2.84% 34.94%
31.81
4.88
29.62% 20.49%
6.9B
988.7M
40.66% 50.03%
-13.86
7
27.41% 8.51%
3.9B
919.1M
17.21% 17.06%
-147.97
4.28
73.02% -172.93%
3.0B
535.8M
8.75% -45.64%
-7.02
5.66
24.38% 26.34%
SMALL-CAP
531.2M
297.1M
54.98% -22.82%
-5.87
1.79
-6.74% -21.60%
71.5M
21.4M
-81.47% -93.49%
-0.62
3.34
-8.80% -39.66%
31.2M
9.2M
-11.33% -33.68%
-1.76
3.4
16.43% 48.38%
12.0M
13.4M
-4.35% -39.31%
-1.21
0.9
-26.43% -20.54%
120.4K
-
-82.76% -93.43%
0
0.76
-57.78% -93.13%

Natera Inc News

Latest updates
Insider Monkey10 Dec 202304:59 pm9 hours ago
MarketBeat07 Dec 202311:02 pm3 days ago
DirectorsTalk Interviews07 Dec 202301:08 pm3 days ago
Marketscreener.com07 Dec 202312:33 pm3 days ago
Defense World03 Dec 202307:48 am7 days ago
Yahoo Finance02 Dec 202312:06 pm8 days ago
Nasdaq01 Dec 202309:00 pm9 days ago
MarketBeat01 Dec 202304:22 pm9 days ago
Securities.io18 Nov 202308:00 am22 days ago
Business Wire14 Nov 202308:00 am26 days ago
Simply Wall St10 Nov 202308:00 am30 days ago
Business Wire08 Nov 202308:00 am32 days ago
Yahoo Finance08 Nov 202308:00 am32 days ago
Marketscreener.com07 Nov 202308:00 am33 days ago
Nasdaq07 Nov 202308:00 am33 days ago

Financials for Natera Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue2.6%268,306,000261,404,000241,756,000217,252,000210,637,000198,200,000194,133,000173,028,000158,116,000142,026,000152,316,000112,378,00098,143,00086,472,00094,012,00083,240,00077,909,00074,355,00066,824,00066,965,00065,280,000
Costs and Expenses1.5%379,288,000373,830,000380,057,000359,025,000329,689,000341,285,000331,263,000312,694,000308,313,000257,320,000215,333,000186,346,000153,920,000138,132,000128,884,000118,051,00099,003,000102,991,00098,570,00096,692,00092,446,000
  S&GA Expenses1.5%154,742,000152,508,000149,627,000143,822,000147,667,000149,468,000147,634,000146,761,000128,485,000127,456,000108,332,00094,080,00075,678,00068,188,00065,681,00058,587,00056,715,00047,042,00043,832,00041,133,00038,374,000
  R&D Expenses-1.2%77,235,00078,173,00082,306,00087,911,00065,510,00082,580,00080,414,00071,811,00098,457,00053,752,00040,188,00032,384,00026,421,00023,005,00018,225,00015,002,00012,796,00012,124,00011,435,00012,770,00012,393,000
EBITDA Margin8.8%-0.47-0.52-0.59-0.63-0.67-0.76-0.79-0.72-0.68-0.58-0.52-0.53-0.46-0.38-0.30------
Interest Expenses2.4%3,252,0003,177,0003,061,0002,752,0002,330,0002,150,0002,087,0002,079,0002,078,0002,075,0002,073,0004,310,0004,270,0004,038,0002,464,0002,576,0002,672,0002,721,0002,724,0002,746,0002,781,000
Income Taxes171.6%202,000-282,000160,000443,000185,000193,000179,000-48,000272,000242,000134,00035,00025,00015,00023,000-14,00044,0001,895,00074,000-14,000118,000
Earnings Before Taxes2.0%-108,828,000-111,085,000-136,777,000-142,152,000-121,295,000-144,958,000-138,416,000-140,594,000-151,001,000-115,784,000-63,719,000-76,376,500-58,298,000-59,622,000-35,349,000-35,197,000-23,093,000-30,521,000-34,017,000-31,855,000-29,498,000
EBT Margin8.1%-0.50-0.55-0.63-0.67-0.70-0.79-0.82-0.75-0.72-0.62-0.57-0.59-0.52-0.45-0.38------
Net Income1.6%-109,030,000-110,803,000-136,937,000-142,573,000-121,480,000-145,151,000-138,595,000-140,564,000-151,273,000-116,026,000-63,853,000-76,411,500-58,323,000-59,637,000-35,372,000-35,183,000-23,137,000-32,416,000-34,091,000-31,841,000-29,616,000
Net Income Margin8.1%-0.51-0.55-0.63-0.67-0.70-0.80-0.82-0.75-0.72-0.62-0.57-0.59-0.52-0.45-0.38------
Free Cashflow55.7%-38,656,000-87,353,000-92,488,000-92,954,000-114,457,000-118,625,000-153,162,000-107,739,000-104,197,000-79,194,000-85,136,000-80,833,000-35,073,000-43,193,000-43,017,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets15.9%1,4471,2481,3191,3941,0091,0671,1451,2361,311850894932977723559583380383261268277
  Current Assets18.9%1,2671,0661,1291,2128309029801,0931,191740791863916664497523324322208241249
    Cash Equivalents75.5%66938140346657.0091.0015985.0095.0063.0065.0049.0021077.0074.0062.0052.0030.0035.0051.0039.00
  Inventory-1.4%42.0043.0041.0035.0040.0030.0025.0027.0028.0028.0024.0020.0020.0018.0014.0012.0013.0015.0014.0014.0012.00
  Net PPE1.9%10510310192.0087.0082.0078.0066.0059.0049.0040.0033.0028.0026.0027.0023.0019.0022.0023.0024.0025.00
Liabilities1.6%662652668689647622602583552551521446441419300304296290256236221
  Current Liabilities4.7%290277291310267252231219200198167199196176177180138127113114102
  Short Term Borrowings0%80.0080.0080.0080.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.00
Shareholder's Equity31.6%78559665170636244554265375929937248653630425927985.0093.005.0032.0057.00
  Retained Earnings-5.0%-2,299-2,190-2,079-1,942-1,800-1,678-1,533-1,394-1,254-1,100-986-929-852-794-734-699-663-640-699-574-542
  Additional Paid-In Capital10.5%3,0892,7962,7422,6652,1812,1402,0902,0502,0121,4001,3561,4111,3841,093988977748733614607600
Shares Outstanding4.3%11911411311197.0097.0096.0095.0093.0088.0087.0086.0079.0079.0078.0078.0070.0066.0063.0058.0061.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations62.3%-29.55-78.39-80.89-81.13-102-110-137-98.74-91.06-70.56-74.88-73.30-33.13-40.98-35.1019.00-48.39-35.75-31.82-12.81-23.27
  Share Based Compensation29.8%58.0044.0041.0036.0040.0041.0035.0030.0026.0035.0023.0016.0015.0012.007.002.0020.0010.004.004.004.00
Cashflow From Investing72.5%81.0047.0016.0022.0067.0035.0020780.00-43160.0087.00-99.17-110-16543.00-151-71.11-10013.0022.00-60.53
Cashflow From Financing2434.4%2369.002.004681.009.004.009.005558.005.0012.002762104.001611201163.003.00105

NTRA Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Total revenues$ 268,306,000$ 210,637,000$ 771,466,000$ 602,970,000
Cost and expenses    
Research and development77,235,00065,510,000237,714,000228,504,000
Selling, general and administrative154,742,000147,667,000456,877,000444,769,000
Total cost and expenses379,288,000329,689,0001,133,175,0001,002,237,000
Loss from operations(110,982,000)(119,052,000)(361,709,000)(399,267,000)
Interest expense(3,252,000)(2,330,000)(9,490,000)(6,567,000)
Interest and other income, net5,406,00087,00014,509,0001,165,000
Loss before income taxes(108,828,000)(121,295,000)(356,690,000)(404,669,000)
Income tax expense(202,000)(185,000)(80,000)(557,000)
Net loss(109,030,000)(121,480,000)(356,770,000)(405,226,000)
Unrealized gain (loss) on available-for-sale securities, net of tax3,807,000(3,212,000)10,966,000(17,322,000)
Comprehensive loss$ (105,223,000)$ (124,692,000)$ (345,804,000)$ (422,548,000)
Net Loss per Share    
Basic (in dollars per share)$ (0.95)$ (1.25)$ (3.14)$ (4.20)
Diluted (in dollars per share)$ (0.95)$ (1.25)$ (3.14)$ (4.20)
Weighted-average number of shares used in computing basic and diluted net loss per share:    
Basic (in shares)115,17197,052113,55996,408
Diluted (in shares)115,17197,052113,55996,408
Product    
Revenues    
Total revenues$ 265,218,000$ 199,831,000$ 761,271,000$ 584,415,000
Cost and expenses    
Cost of revenues146,962,000115,436,000437,524,000326,862,000
Licensing and other    
Revenues    
Total revenues3,088,00010,806,00010,195,00018,555,000
Cost and expenses    
Cost of revenues$ 349,000$ 1,076,000$ 1,060,000$ 2,102,000

NTRA Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash, cash equivalents and restricted cash$ 668,710$ 466,091
Short-term investments267,847432,301
Accounts receivable, net of allowance of $6,034 and $3,830 at September 30, 2023 and December 31, 2022, respectively255,147244,385
Inventory42,07635,406
Prepaid expenses and other current assets, net33,49633,634
Total current assets1,267,2761,211,817
Property and equipment, net104,83092,453
Operating lease right-of-use assets58,20671,874
Other assets16,20818,330
Total assets1,446,5201,394,474
Current liabilities:  
Accounts payable21,32131,148
Accrued compensation39,41544,010
Other accrued liabilities133,740144,214
Deferred revenue, current portion15,01210,777
Short-term debt financing80,43580,350
Total current liabilities289,923310,499
Long-term debt financing282,619281,653
Deferred revenue, long-term portion21,03320,001
Operating lease liabilities, long-term portion68,28776,577
Total liabilities661,862688,730
Commitments and contingencies (Note 8)
Stockholders' equity:  
Common stock, $0.0001 par value: 750,000 shares authorized at both September 30, 2023 and December 31, 2022; 118,990 and 111,255 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1111
Additional paid in capital3,089,4482,664,730
Accumulated deficit(2,299,405)(1,942,635)
Accumulated other comprehensive loss(5,396)(16,362)
Total stockholders' equity784,658705,744
Total liabilities and stockholders' equity$ 1,446,520$ 1,394,474
NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
 CEO
 WEBSITEwww.natera.com
 EMPLOYEES2958

Natera Inc Frequently Asked Questions


What is the ticker symbol for Natera Inc? What does NTRA stand for in stocks?

NTRA is the stock ticker symbol of Natera Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Natera Inc (NTRA)?

As of Fri Dec 08 2023, market cap of Natera Inc is 6.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTRA stock?

You can check NTRA's fair value in chart. The fair value of Natera Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Natera Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NTRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Natera Inc a good stock to buy?

The fair value guage provides a quick view whether NTRA is over valued or under valued. Whether Natera Inc is cheap or expensive depends on the assumptions which impact Natera Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRA.

What is Natera Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NTRA's PE ratio (Price to Earnings) is -13.86 and Price to Sales (PS) ratio is 7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRA PE ratio will change depending on the future growth rate expectations of investors.